Published in Am J Physiol Heart Circ Physiol on January 07, 2011
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation (2011) 2.48
Environmentally persistent free radicals decrease cardiac function and increase pulmonary artery pressure. Am J Physiol Heart Circ Physiol (2012) 0.99
Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. Circ Res (2011) 0.94
Insights into BAY 60-2770 activation and S-nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous nostoc H-NOX domain complexes. Biochemistry (2013) 0.88
Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. Crit Care Res Pract (2012) 0.87
Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling. Curr Hypertens Rep (2013) 0.86
Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat. Am J Physiol Heart Circ Physiol (2013) 0.86
Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway. PLoS One (2012) 0.85
Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Clin Pharmacol Ther (2014) 0.83
Direct sGC activation bypasses NO scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction. Antioxid Redox Signal (2013) 0.81
The sGC activator BAY 60-2770 has potent erectile activity in the rat. Am J Physiol Heart Circ Physiol (2013) 0.81
Analysis of responses to glyceryl trinitrate and sodium nitrite in the intact chest rat. Nitric Oxide (2012) 0.81
Vasodilator responses to acetylcholine are not mediated by the activation of soluble guanylate cyclase or TRPV4 channels in the rat. Am J Physiol Heart Circ Physiol (2014) 0.80
Analysis of erectile responses to imatinib in the rat. Urology (2013) 0.79
The selective Rho-kinase inhibitor azaindole-1 has long-lasting erectile activity in the rat. Urology (2013) 0.78
Endothelin-1 and endothelin-2 initiate and maintain contractile responses by different mechanisms in rat mesenteric and cerebral arteries. Br J Pharmacol (2013) 0.78
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. Expert Rev Respir Med (2011) 0.77
The soluble guanylyl cyclase activator BAY 60-2770 potently relaxes the pulmonary artery on congenital diaphragmatic hernia rabbit model. Pediatr Surg Int (2014) 0.76
Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm. Pflugers Arch (2014) 0.76
Soluble guanylyl cyclase-activated cyclic GMP-dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP-serine 239 phosphorylation. Cell Signal (2016) 0.75
Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A (1977) 4.90
Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res (1987) 4.42
Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol (1995) 4.36
Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry (1994) 2.65
Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest (2006) 2.52
Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med (2010) 2.12
Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta (1982) 2.00
NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol (2002) 1.90
A molecular basis for nitric oxide sensing by soluble guanylate cyclase. Proc Natl Acad Sci U S A (1999) 1.86
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension (2007) 1.84
Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation (2009) 1.76
Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide. Biochemistry (1996) 1.75
Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proc Natl Acad Sci U S A (1994) 1.58
Inhibition of soluble guanylate cyclase by ODQ. Biochemistry (2000) 1.58
NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol (2009) 1.45
Requirement for heme in the activation of purified guanylate cyclase by nitric oxide. Biochim Biophys Acta (1983) 1.38
Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol (2002) 1.26
Relaxation of intrapulmonary artery and vein by nitrogen oxide-containing vasodilators and cyclic GMP. J Pharmacol Exp Ther (1984) 1.23
Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol (2002) 1.20
Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase. Neuroscience (1995) 1.20
Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung (2008) 1.05
Effects of thiols, sugars, and proteins on nitric oxide activation of guanylate cyclase. J Biol Chem (1979) 1.05
Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation. J Pharmacol Exp Ther (2000) 1.01
Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol (2008) 0.99
Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. Eur J Cardiothorac Surg (2010) 0.96
The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol (2009) 0.94
Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide. Am J Physiol Heart Circ Physiol (2010) 0.93
Inhibition by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of responses to nitric oxide-donors in rat pulmonary artery: influence of the mechanism of nitric oxide generation. J Pharm Pharmacol (1999) 0.89
Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. Am J Physiol Lung Cell Mol Physiol (2009) 0.84
Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure. Clin Pharmacokinet (2010) 0.80
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
Dexmedetomidine: a review of clinical applications. Curr Opin Anaesthesiol (2008) 2.65
RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A (2004) 2.53
Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med (2010) 2.12
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension (2007) 1.84
Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol (2006) 1.65
Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem (2003) 1.61
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation (2006) 1.55
Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension (2006) 1.50
Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. Am J Respir Crit Care Med (2014) 1.48
Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res (2011) 1.47
NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol (2009) 1.45
Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. Am J Physiol Heart Circ Physiol (2006) 1.41
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem (2009) 1.36
Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J Biol Chem (2010) 1.34
Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl (2003) 1.32
Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res (2009) 1.29
Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol (2002) 1.25
Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol (2003) 1.22
Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins. J Clin Hypertens (Greenwich) (2012) 1.19
Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest (2010) 1.18
The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl (2013) 1.18
Pulmonary vasodilator responses to sodium nitrite are mediated by an allopurinol-sensitive mechanism in the rat. Am J Physiol Heart Circ Physiol (2008) 1.17
Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab (2012) 1.15
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens (2010) 1.15
Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice. Proc Natl Acad Sci U S A (2002) 1.11
Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase. Eur J Pharmacol (2005) 1.11
Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med (2005) 1.10
Nucleotidyl cyclase activity of soluble guanylyl cyclase α1β1. Biochemistry (2011) 1.05
Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung (2008) 1.05
Dimerization region of soluble guanylate cyclase characterized by bimolecular fluorescence complementation in vivo. Mol Pharmacol (2007) 1.04
BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. Eur Heart J (2009) 1.04
Adipose tissue-derived stem cell-seeded small intestinal submucosa for tunica albuginea grafting and reconstruction. Proc Natl Acad Sci U S A (2012) 1.04
Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One (2011) 1.04
Identification of residues crucially involved in soluble guanylate cyclase activation. FEBS Lett (2006) 1.00
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One (2012) 1.00
Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol (2003) 0.99
Environmentally persistent free radicals decrease cardiac function and increase pulmonary artery pressure. Am J Physiol Heart Circ Physiol (2012) 0.99
Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol (2004) 0.98
The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc (2013) 0.98
Engineering ex vivo-expanded marrow stromal cells to secrete calcitonin gene-related peptide using adenoviral vector. Stem Cells (2004) 0.97
Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation (2002) 0.97
Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs (2011) 0.96
Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am J Physiol Heart Circ Physiol (2012) 0.96
Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. Eur J Cardiothorac Surg (2010) 0.96
Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med (2007) 0.96
Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2011) 0.95
Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. Am J Physiol Heart Circ Physiol (2012) 0.95
NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol (2006) 0.95
Dexmedetomidine: clinical application as an adjunct for intravenous regional anesthesia. Anesthesiol Clin (2010) 0.94
Gene transfer of extracellular SOD to the penis reduces O2-* and improves erectile function in aged rats. Am J Physiol Heart Circ Physiol (2002) 0.93
Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide. Am J Physiol Heart Circ Physiol (2010) 0.93
Purinergic (P2) receptor control of lower genitourinary tract function and new avenues for drug action: an overview. Curr Pharm Des (2007) 0.93
Nitrates and nitrites in the treatment of ischemic cardiac disease. Cardiol Rev (2010) 0.92
Adenoviral gene transfer of eNOS: high-level expression in ex vivo expanded marrow stromal cells. Am J Physiol Cell Physiol (2003) 0.92
The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats. Diab Vasc Dis Res (2010) 0.91
Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat. Am J Physiol Lung Cell Mol Physiol (2008) 0.90
Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res (2009) 0.90
Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure. J Am Soc Nephrol (2006) 0.90
Mitochondrial aldehyde dehydrogenase mediates vasodilator responses of glyceryl trinitrate and sodium nitrite in the pulmonary vascular bed of the rat. Am J Physiol Heart Circ Physiol (2010) 0.89
Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation (2003) 0.89
Vascular responses to nitrite are mediated by xanthine oxidoreductase and mitochondrial aldehyde dehydrogenase in the rat. Can J Physiol Pharmacol (2009) 0.88
Insights into BAY 60-2770 activation and S-nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous nostoc H-NOX domain complexes. Biochemistry (2013) 0.88
Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade. PLoS One (2012) 0.88
Vasoactive prostanoids are generated from arachidonic acid by COX-1 and COX-2 in the mouse. Am J Physiol Heart Circ Physiol (2005) 0.88
BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase. Biochem Biophys Res Commun (2002) 0.88
A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. Anal Biochem (2005) 0.88
Cardiovascular effects of peroxynitrite. Clin Exp Pharmacol Physiol (2007) 0.87
Receptor binding assay for nitric oxide- and heme-independent activators of soluble guanylate cyclase. Anal Biochem (2003) 0.87
Role of cyclooxygenase-2 in the generation of vasoactive prostanoids in the rat pulmonary and systemic vascular beds. Circulation (2003) 0.87
NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size. Cardiovasc Res (2013) 0.86
Tetrahydrobiopterin protects soluble guanylate cyclase against oxidative inactivation. Mol Pharmacol (2012) 0.86
Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat. Am J Physiol Heart Circ Physiol (2013) 0.86
Effects of salsalate therapy on recovery from vascular injury in female Zucker fatty rats. Diabetes (2010) 0.86
Rho kinase and Ca2+ entry mediate increased pulmonary and systemic vascular resistance in L-NAME-treated rats. Am J Physiol Lung Cell Mol Physiol (2007) 0.86
Superoxide dismutase - a target for gene therapeutic approach to reduce oxidative stress in erectile dysfunction. Methods Mol Biol (2010) 0.85
Effect of chronic sodium nitrite therapy on monocrotaline-induced pulmonary hypertension. Nitric Oxide (2012) 0.85
Advances in perioperative pain management: use of medications with dual analgesic mechanisms, tramadol & tapentadol. Anesthesiol Clin (2010) 0.85